Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection

BACKGROUND: The progression from acute to chronic antibody-mediated rejection in kidney transplant recipients is usually not prevented by current therapeutic options. Here, we investigated whether the use of tofacitinib (TOFA), a Janus kinase 3 inhibitor, was capable of preventing the progression of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transplantation
Main Authors: Rovira, Jordi, Ramírez-Bajo, María José., Banon-Maneus, Elisenda, Lazo-Rodríguez, Marta, Moya-Rull, Daniel, Hierro-Garcia, Natalia, Tubita, Valeria, Piñeiro, Gastón J., Revuelta, Ignacio, Ventura-Aguiar, Pedro, Cucchiari, David, Oppenheimer, Federico, Brunet, Mercè, Campistol, Josep M., Diekmann, Fritz
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer 2018
Assuntos:
Original Basic Science—General
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7228626/
https://ncbi.nlm.nih.gov/pubmed/29620612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0000000000002204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados